Iranian
Biomedical Journal
Volume 26, Issue 1 (1-2022)
IBJ 2022, 26(1): 64-69 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
cheraghi S, asadzadeh H, javadi G R. Dysregulated Expression of Long Non-Coding RNA MINCR and EZH2 in Colorectal Cancer. IBJ 2022; 26 (1) :64-69
URL: http://ibj.pasteur.ac.ir/article-1-3218-en.html
URL: http://ibj.pasteur.ac.ir/article-1-3218-en.html
Abstract:
Background: As critical regulators, lncRNAs have attracted attention from researchers for diagnostic, prognostic, and therapeutic purposes in human carcinogenesis via interfering with mRNAs such as EZH2. Nevertheless, the potent roles and molecular mechanisms of these RNAs in CRC are not clearly known. Methods: In this study, the tissue expressions of lncRNA MINCR and EZH2 mRNA between colorectal tumors and polyps were compared
with the adjacent normal tissues collected from 114 Iranian patients, using real-time PCR method. Furthermore, the correlation of the expression levels of MINCR and EZH2 with other clinical parameters was evaluated. Results: The significant overexpression of MINCR and EZH2 were observed in the CRC tissues compared to control tissues (p < 0.0001). This observation confirmed the association of these expression enhancements with the pathological stage of CRC patients. Conclusion: Our findings revealed that the expression of MINCR significantly alters during CRC development, and it can be identified as a potential biomarker for the detection of CRC.
with the adjacent normal tissues collected from 114 Iranian patients, using real-time PCR method. Furthermore, the correlation of the expression levels of MINCR and EZH2 with other clinical parameters was evaluated. Results: The significant overexpression of MINCR and EZH2 were observed in the CRC tissues compared to control tissues (p < 0.0001). This observation confirmed the association of these expression enhancements with the pathological stage of CRC patients. Conclusion: Our findings revealed that the expression of MINCR significantly alters during CRC development, and it can be identified as a potential biomarker for the detection of CRC.
Type of Study: Full Length/Original Article |
Subject:
Cancer Biology
References
1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przeglad GastroenterologicZNY 2019; 14(2): 89-103. [DOI:10.5114/pg.2018.81072]
2. Guler I, Askan G, Klostergaard J, Sahin IH. Precision medicine for metastatic colorectal cancer: an evolving era. Expert review of gastroenterology and hepatology 2019; 13(10): 919-931. [DOI:10.1080/17474124.2019.1663174]
3. Pellino G, Gallo G, Pallante P, Capasso R, De Stefano S, Maretto I, Malapelle U, Qiu Sh, Nikolaou S, Barina A, Clerico G, Reginelli A, Giuliani A, Sciaudone G, Kontovounisios C, Brunese L, Trompetto M, Selvaggi F. Noninvasive biomarkers of colorectal cancer: Role in diagnosis and personalised treatment perspectives. Gastroenterology research and practice 2018; 2018: 2397863. [DOI:10.1155/2018/2397863]
4. Gonzalez-Pons M, Cruz-Correa M. Colorectal cancer biomarkers: Where are we now? BioMed research international 2015; 2015: 149014. [DOI:10.1155/2015/149014]
5. Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature 2012; 482(7385): 339. [DOI:10.1038/nature10887]
6. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes and development 2009; 23(13): 1494-1504. [DOI:10.1101/gad.1800909]
7. Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Küppers R, Lenze D, Ott G, Pott Ch, Richter J, Rosenwald A, Szczepanowski M, Schwaenen C, Stein H, Trautmann H, Wessendorf S, Trümper L, Loeffler M, Spang R, Kluin PM, Klapper W, Siebert R. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica 2014; 99(4): 726-735. [DOI:10.3324/haematol.2013.091827]
8. Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. The international journal of biochemistry and cell biology 2013; 45(8): 1895-1910. [DOI:10.1016/j.biocel.2013.05.030]
9. Doose G, Haake A, Bernhart SH, López C, Duggimpudi S, Wojciech F, Bergmann AK, Borkhardt A, Burkhardt B, Claviez A, Dimitrova L, Haas S, Hoell JI, Hummel M, Karsch D, Klapper W, Kleo K, Kretzmer H, Kreuz M, Küppers R, Lawerenz C, Lenze D, Loeffler L, Mantovani-Löffler L, Möller P, Ott G, Richter J, Rohde M, Rosenstiel P, Rosenwald A, Schilhabel M, Schneider M, Scholz I, Stilgenbauer S, Stunnenberg HG, Szczepanowski M, Trümper L, Weniger MA. MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in burkitt lymphoma cells. Proceedings of the national academy of sciences of the United States of America 2015; 112(38): E5261-E5270. [DOI:10.1073/pnas.1505753112]
10. Sabò A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli MJ, Bora P, Doni M, Verrecchia A, Tonelli C, Fagà G, Bianchi V, Ronchi A, Low D, Müller H, Guccione E, Campaner S, Amati B. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 2014; 511(7510): 488-492. [DOI:10.1038/nature13537]
11. Kim T, Jun Jeon Y, Cui R, Hoon Lee J, Peng Y, Hak Kim S, Tili E, Alder H, Croce CM. Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis. Journal of the national cancer institute 2015; 107(4): dju505. [DOI:10.1093/jnci/dju505]
12. Cao J, Zhang D, Zeng L, Liu F. Long noncoding RNA MINCR regulates cellular proliferation, migration, and invasion in hepatocellular carcinoma. Biomedicine pharmacother 2018; 102: 102-106. [DOI:10.1016/j.biopha.2018.03.041]
13. Wang SH, Yang Y, Cai Wu X, Di Zhang M, Zhe Weng M, Zhou D, Dong Wang J, Wei Quan Z. Long non-coding RNA MINCR promotes gallbladder cancer progression through stimulating EZH2 expression. Cancer letters 2016; 380(1): 122-133. [DOI:10.1016/j.canlet.2016.06.019]
14. Golbabapour S, Golbabapour SH, Abdul Majid N, Hassandarvish P, Hajrezaie M, Abdulla MA, Hadi HA. Gene silencing and polycomb group proteins: an overview of their structure, mechanisms and phylogenetics. Omics 2013; 17(6): 283-296. [DOI:10.1089/omi.2012.0105]
15. Laugesen A, Højfeldt JW, Helin K. Role of the polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancer. Cold spring harbor perspectives in medicine 2016; 6(9): a026575. [DOI:10.1101/cshperspect.a026575]
16. Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomarker research 2018; 6(1): 10. [DOI:10.1186/s40364-018-0122-2]
17. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell stem cell 2010; 7(3): 299-313. [DOI:10.1016/j.stem.2010.08.002]
18. Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. Journal of hematology and oncology 2020; 13(1): 104. [DOI:10.1186/s13045-020-00937-8]
19. Waliullah S, Hudson O, Oliver JE, Brannen PM, Ji P, Emran Ali Md. Comparative analysis of different molecular and serological methods for detection of Xylella fastidiosa in blueberry. PLoS one 2019; 14(9): e0221903. [DOI:10.1371/journal.pone.0221903]
20. Akhoond MR, Kazemnejad A, Hajizadeh E, Ganbary Motlagh A, Zali MR. Comparison of influential factors affecting survival of patients with colon and rectum cancer using competing risks model. Koomesh 2011; 12(2): 119-128.
21. Sun M, Nie F, Wang Zh, De D. Involvement of lncRNA dysregulation in gastric cancer. Histology and histopathology 2016; 31(1): 33-39.
22. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Henry K, Pinchback RM, Ligon AH, Cho Y, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao M, Demichelis F, Rubin M, Janne PA, Daly MJ, Nucera C, Levine R, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway A, Loda M, Beer D, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463(7283): 899-905. [DOI:10.1038/nature08822]
23. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Eynde AV, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Croce LD, Launoit Y, Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439(7078): 871. [DOI:10.1038/nature04431]
24. Sato T, Kaneda A, Tsuji S, Isagawa T, Yamamoto S, Fujita T, Yamanaka R, Tanaka Y, Nukiwa T, Marquez VE, Ishikawa Y, Ichinose M, Aburatani H. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Scientific reports 2013; 3: 1911. [DOI:10.1038/srep01911]
25. Crea F, Hurt EM, Farrar WL. Clinical significance of polycomb gene expression in brain tumors. Molecular cance 2010; 9(1): 265. [DOI:10.1186/1476-4598-9-265]
26. Chen JF, Luo X, Xiang LS, Li HT, Zha L, Li N, He JM, Xie GF, Xie X, Liang HJ. EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling. Oncotarget 2016; 7(27): 41540-41558. [DOI:10.18632/oncotarget.9236]
27. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt R, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the national academy of sciences 2003; 100(20): 11606-11611. [DOI:10.1073/pnas.1933744100]
28. Kuang Y, Lu F, Guo J, Xu H, Wang Q, Xu CH, Zeng L, Yi S. Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo. Oncotargets and therapy 2017; 10: 3131. [DOI:10.2147/OTT.S134784]
29. Trošelj KG, Kujundzic RN, Ugarkovic D. Polycomb repressive complex's evolutionary conserved function: The role of EZH2 status and cellular background. Clinical epigenetics 2016; 8(1): 55. [DOI:10.1186/s13148-016-0226-1]
30. Lu H, Li G, Zhou C, Jin W, Qian X, Wang ZH, Pan H, Jin H, Wang X. Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development. American journal of cancer research 2016; 6(12): 2737.
31. Wen Y, Cai J, Hou Y, Huang Z, Wang Z. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target. Oncotarget 2017; 8(23): 37974. [DOI:10.18632/oncotarget.16467]
32. Boostani F, Dolatkhah R, Fakhrjou A, Farassati F, Sanaat Z. Association of clinicopathologic characteristics and outcomes with EZH2 expression in patients with breast cancer in East Azerbaijan, Iran. Oncotargets and therapy 2018; 11: 449-457. [DOI:10.2147/OTT.S149210]
33. Yamamoto I, Nosho K, Kanno SH, Igarashi H, Kurihara H, Ishigami K, Ishiguro K, Mitsuhashi K, Maruyama R, Koide H, Okuda H, Hasegawa T, Sukawa K, Okita K, Takemasa I, Yamamoto H, Shinomura Y, Nakase H. EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics. Oncotarget 2017; 8(11): 17810-17818. [DOI:10.18632/oncotarget.14863]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |